OUR PLATFORMS
Technology platforms to power true precision in oncology testing.1,2
Guardant Complete liquid and tissue biopsies are powered by the Guardant Infinity™ and Guardant Galaxy™ platforms.2,3*
Guardant Infinity is the first and only platform to combine genomic and epigenomic profiling via liquid biopsy to offer a truly multidimensional view of cancer, now commercially available through our products.1
See what’s next now with the Guardant Infinity platform
In a clinical setting, Guardant products powered by the Infinity platform can have:
Even faster turnaround times
post-sample receipt1
Enhanced sensitivity
with 100x to 1000x more signals available to analyze1
New insights
across the continuum of care, from minimal residual disease to progression1
Profiling
Precision oncology has advanced our ability to match the right patient to the right treatment at the right time—and we are just getting started.
A new dimension of insights: An epigenomics example1,4
Genomic profiling offers details into alterations of the genomic DNA…
...while epigenomic profiling can help detect alterations to the expression of the genome.4,5
The epigenome is a dynamic landscape providing breakthrough insights to offer a more complete view of cancer.4,6,7
Epigenetics
A growing body of evidence demonstrates that epigenetic changes have a tremendous impact on cancer development and progression.4,6
Epigenomic insights, specifically methylation sequencing, can advance multiple precision oncology applications.1
An AI-backed algorithm that’s available with the Guardant360
TissueNext™ PD-L1 test to keep you on the cutting edge of PD-L1
detection technology.2
AI-backed digital pathology algorithm that is now validated for multiple cancer types.2‡
Accurate scoring helps to predict response to immunotherapy.10
Orderable through Guardant360 TissueNext with PD-L1—results in 2 to 3 weeks.2
Data
A more precise PD-L1 test for non-small cell lung cancer (NSCLC).2,11
>20%
improved PD-L1 detection
improved PD-L1 detection
AI-powered PD-L1 scoring that accurately classified 22.2% of patients, initially identified as Tumor Proportion Score (TPS) <1%.2,11§
Response rate
up to 62%
In KEYNOTE-189, overall response rates ranged from 33.1% to 62.1%,
depending on TPS.2,10
*Guardant Infinity is not available for patients with advanced-stage cancer tested with any Guardant liquid biopsies.
†Compared with genomic-only detection.1
‡Guardant360 TissueNext PD-L1 test powered by Guardant Galaxy is available for NSCLC, breast, urothelial, hepatobiliary, gastric, colorectal, pancreatic, and prostate cancers. Some cases may require conventional determination of PD-L1 status without AI.2
§Compared to manual pathologist interpretation in the most challenging cases in NSCLC.11
AI, artificial intelligence; MRD, minimal residual disease; PD-L1, programmed death-ligand 1.
References: 1. Guardant Health data on file: Guardant Infinity. Guardant Health, Inc. Redwood City, CA. 2. Guardant Health data on file: Guardant Galaxy. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health data on file: Guardant Reveal on Infinity. Guardant Health, Inc. Redwood City, CA. 4. Muthamilselvan S, Raghavendran A, Palaniappan A. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression. PLoS One.2022;17(2):e0249151. doi:10.1371/journal.pone.0249151 5. NCI Dictionary of Cancer Terms. Definition of Genomic Profiling. Accessed July 25, 2023. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/genomic-profiling 6. Watts GS, Futscher BW, Holtan N, Degeest K, Dorman FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008;1:47. doi:10.1186/1755-8794-1-47 7. Yoshimi A, Lin KT, Wiseman DH, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019;574(7777):273-277. doi:10.1038/s41586-019-1618-0 8. Berchuck JE, Baca SC, McClure HM, et al. Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis. Clin Cancer Res. 2022;28(5):929-938. doi:10.1158/1078-0432.CRR-21-3762 9. Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. 2018; 9(1):3970. doi:10.1038/s41467-018-05564-z 10. Rodriguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specificed final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881-895. doi:10.1016/j.annonc.2021/04.008 11. Choi S, Cho SI, Ma M, et al. Artifical intelligence—powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response. Eur J Cancer. 2022;170:17-26. doi:10.1016/j.ejca.2022.04.011